- InMed to test INM-750 in vitro, estimates clinical trials for 2018-2020
- ATERA SAS to develop 3D skin models to help pre-clinical tests of INM-750
- INM-750 being developed to treat skin disease epidermolysis bullosa, with a successful therapy having potential global market of $1 billion
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a biopharmaceutical company focused on identifying and commercializing prescription drugs using non-THC cannabinoids, recently reached a research and development agreement with tissue engineering company ATERA SAS of France (http://nnw.fm/5t7cL). The fundamental benefits of this agreement for InMed, as it eyes a clinical trial program, are a proprietary assessment tool, a biosynthesis manufacturing process, and drug development programs.
Vancouver-based InMed’s lead compound is INM-750, a proprietary topical cannabinoid product candidate aimed at treating skin disease epidermolysis bullosa (EB). EB is a skin disease which retards wound healing and can cause pain, itching, and inflammation. INM-750 may reverse the disease, for which there are currently no approved therapies. In its corporate presentation, InMed said that it sees a potential global market of $1 billion for INM-750, if approved.
ATERA SAS, as part of the agreement, will develop 3D human skin models that will assist InMed in assessing INM-750’s effectiveness in treating EB in vitro ahead of upcoming clinical trials estimated by InMed to take place in 2018, 2019 and 2020. ATERA SAS will produce 3D skin models in a controlled environment, creating a unique tool for drug development screening. ATERA SAS is expected to develop the 3D models from EB patient biopsies in order to help InMed assess INM-750.
ATERA SAS is a tissue engineering company tasked in this agreement with developing advanced human tissue models to assist InMed in analyzing pre-trial tests. The French company will also investigate INM-750 at the ultra-structural cellular and molecular levels. It will create 3D in vitro reconstructed human full thickness skin models of both normal and EB-derived skin cells.
At InMed, Dr. Ado Muhammed, MD, DPM and MFPM, is the chief medical officer. He previously served as associate medical director at GW Pharmaceuticals, where he was key in leading the company in the development and FDA approval of one of the first cannabis drugs. InMed is the only cannabis biotech company led by a former GW Pharmaceuticals executive.
For more information, visit the company’s website at www.InMedPharma.com
More from NetworkNewsWire
SinglePoint, Inc. (SING) Offers New Investor Relations Kit to Financial Community
Moxian, Inc. (NASDAQ: MOXC) Changes Venue and Record Date for its 2017 General Meeting of Stockholders
ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Looks Strong for Investors in Booming Canadian Cannabis Market
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
No comments:
Post a Comment